| Arthritis, Psoriatic
Sotyktu vs Taltz
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Sotyktu vs Taltz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTaltz has a higher rate of injection site reactions vs Sotyktu based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Taltz but not Sotyktu, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sotyktu
Taltz
At A Glance
Oral
Daily
TYK2 inhibitor
SC injection
Every 4 weeks (maintenance)
IL-17A antagonist
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
Dosing
Psoriasis vulgaris, Arthritis, Psoriatic 6 mg orally once daily, with or without food; do not crush, cut, or chew tablets; not recommended in severe hepatic impairment (Child-Pugh C).
Psoriasis vulgaris 160 mg SC at Week 0, then 80 mg at Weeks 2, 4, 6, 8, 10, 12, followed by 80 mg every 4 weeks.
Arthritis, Psoriatic 160 mg SC at Week 0, followed by 80 mg every 4 weeks.
Ankylosing spondylitis, Non-Radiographic Axial Spondyloarthritis 160 mg SC at Week 0, followed by 80 mg every 4 weeks.
Contraindications
- History of hypersensitivity reaction to deucravacitinib or any excipient in SOTYKTU
- Previous serious hypersensitivity reaction to ixekizumab or to any of the excipients
Adverse Reactions
Most common (>=1%) Upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, acne
Serious Pneumonia, COVID-19, malignancies including breast cancer, hepatocellular carcinoma, and lymphoma
Most common (>=1%) Injection site reactions, upper respiratory tract infections, nausea, tinea infections.
Serious Serious infections, hypersensitivity reactions including anaphylaxis, inflammatory bowel disease.
Pharmacology
TYK2 inhibitor; deucravacitinib binds the regulatory domain of TYK2, allosterically inhibiting receptor-mediated TYK2 activation and downstream STAT signaling via the JAK-STAT pathway.
Humanized IgG4 monoclonal antibody that selectively binds to interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sotyktu
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Taltz
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Sotyktu
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Taltz
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Sotyktu
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Taltz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
$25/momo
Taltz Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SotyktuView full Sotyktu profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.